Stallergenes Greer’s Personalised Allergen Immunotherapy Model Encouraged by Leading Scientists: "Allergy" Journal Publishes Article Today
Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled “Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model” in the EAACI’s (European Academy of Allergy and Clinical Immunology) official journal Allergy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005819/en/
The publication marks a clear consensus on allergen immunotherapy (AIT). It was co-authored by 49 world-renowned allergy specialists from 40 countries and coordinated by Professor Giorgio Walter Canonica, Personalised Medicine, Asthma and Allergy, Humanitas University and Research (Milano, Italy) and Professor Cristoforo Incorvaia, Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, (Milano, Italy), with an unrestricted grant from Stallergenes Greer.
The article demonstrates that there is very strong evidence to show that AIT achieves its primary therapeutic goals in patients with respiratory allergies1,2 by reducing the frequency and intensity of symptoms, the use of rescue medications, and improving quality of life for people with allergies.
Personalised medicine is improving the effectiveness and precision of allergy diagnosis and consequently increasing the performance and treatment outcome of AIT.
“This landmark publication, which is fully aligned with Stallergenes Greer’s commitment, highlights the unique role of AIT in allergy treatment encompassing the prediction of a successful treatment, the potential prevention or progression of an allergic disease, and the possibility of providing such advances at affordable costs,” states Amer Jaber, EVP Operations Europe and President of Stallergenes SAS, who heads Stallergenes Greer's R&D.
AIT: a medical model of personalised healthcare
The article outlines that personalised allergy care is valuable and may also be preventive by focusing on quality of life, predictive by allowing treatment to be adjusted to the individual’s response and participative by empowering the patient.
AIT is consistent with the three major needs to be met in personalised medicine:
- the identification of the molecular mechanism of the disease,
- the availability of diagnostic tools to recognise this mechanism, and
- the availability of a treatment capable of blocking the mechanism3,4.
AIT delivers customised healthcare, with medical decisions, practices, and/or products tailored to the individual patient5.
Leveraging precision medicine for personalised allergy care
This tailor-made approach to diagnosis, decision-making, product choice and treatment schedules may enhance effectiveness, minimise adverse events, improve quality of life and reduce the socio-economic impact of allergies 6,7,8,9.
Stallergenes Greer’s purpose “Enabling precision medicine to improve life for people with allergies” is in line with the statements set out in the article. Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to maximise treatment outcomes for patients with allergies.
Read the full article here: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14575
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at: https://www.stallergenesgreer.com/
1 Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798.
2 Demoly P, et al. The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):640-648.
3 Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010: 22; 363(4):301-4.
4 Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy. 2015: 8;13:24.
5
Canonica GW, et al. Allergen Immunotherapy (AIT): A prototype of precision medicine. World Allergy Organ J. 2015;8 (1), 31 2015.
6 Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016; 137:545-558.
7 Caillot N, et al. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. J Allergy Clin Immunol. 2017;140; 759-770.
8 Gueguen C, et al. IL-10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy. Allergy. 2019; 74:2223-2226.
9 Luce S, et al. Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy. Allergy. 2020; 75:1513-1516.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005819/en/
Contact information
Communications
Catherine Kress
Tel: +33 01 55 59 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacsun Successfully Implements Manhattan Active ® Point of Sale, Unifying Commerce and Cutting Checkout Times19.11.2025 10:00:00 EET | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that Pacsun, a leading youth fashion retailer, has successfully deployed Manhattan Active® Point of Sale (POS), a cloud-native in-store sales and service solution that empowers associates to merge digital convenience with personalised retailing. Following a five-month project start to pilot phase, Pacsun rolled out Manhattan's POS solution across 300 plus stores in just eight weeks. Mobile checkout capabilities eased long in-store lines, while unified inventory management, powered by RFID integration, supported seamless fulfilment across Instagram, Amazon, TikTok and Pacsun’s own channels. During peak holiday season, Pacsun achieved record breaking revenue and streamlined operations, with 40% of online orders being fulfilled via stores, optimising inventory proximity, labour capacity and shipping costs that reduced logistics expenses by 25%. Stores are now critical drivers of retail differentiation, with industry research showing
Aqara's Next-Generation Radiator Thermostat Delivers Smarter, Greener Heating to European Homes19.11.2025 10:00:00 EET | Press release
Aqara, a global leader and pioneer in IoT, today announces the availability of its Radiator Thermostat W600, first unveiled at IFA 2025. Boasting smart features like convenient temperature control, automated climate regulation, and seamless interoperability across Matter ecosystems via Thread/Zigbee protocol, the W600 transforms traditional radiators into intelligent, energy-efficient heating systems that not only enhance comfort but also help reduce energy bills. Designed for sustainable living, the Radiator Thermostat W600 delivers energy savings by minimizing heating in unoccupied areas. Instead of heating the whole home, users can schedule temperature adjustments for individual rooms, with up to 7 time periods per day, aligning with daily routines. Furthermore, these thermostatic radiator valves (TRV) can regulate indoor temperature based on environmental and behavioral triggers like room occupancy and geofencing, allowing for a heating system that adapts to real-time usage and occ
Frontgrade Gaisler and DELTATEC Enable Advanced Space Computing Across Multiple Missions19.11.2025 10:00:00 EET | Press release
Frontgrade™ Gaisler Technologies a leading provider of high-reliability electronic solutions for space and national security missions, and DELTATEC,a very high-level design house specialized in advanced technologies are pleased to celebrate their successful collaboration in delivering high-performance computing solutions for space applications, with the GR712RC dual-core microprocessor at the heart of several flight-proven systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119011567/en/ The GR712RC, developed by Frontgrade Gaisler and based on the fault-tolerant LEON3FT architecture, has been integrated into multiple Data Handling System (DHS) units designed by DELTATEC. These include one Payload Data Handling Unit (PDHU) and two On-Board Computers (OBCs) currently operating aboard ESA’s eSAIL mission, launched into Low Earth Orbit (LEO) in September 2020. Moreover, DELTATEC recently delivered the Flight Model of the
Wasabi Introduces High-Performance Class and Expands into Silicon Valley to Take on AI’s Rising Data Storage Costs19.11.2025 10:00:00 EET | Press release
Wasabi Technologies, the Hot Cloud Storage company, expanded further into artificial intelligence with the unveiling of Wasabi Fire, a high-performance storage class that supports AI workloads, available beginning in early 2026. Wasabi has also opened a new storage region in San Jose, Calif., as part of its relationship with IBM Cloud. The milestones reinforce Wasabi’s push to expand its role in AI infrastructure as demand for scalable, high-performance and cost-efficient cloud storage accelerates. “Object storage is the backbone of AI, but customers shouldn’t have to choose between speed and cost,” said David Friend, co-founder and CEO of Wasabi Technologies. “With Wasabi Fire, we’re delivering NVMe performance at disruptive prices, allowing organizations to cost-effectively store the critical data needed to train AI.” Wasabi Storage Built for the AI Era AI development spend has centered on GPUs, but the rapid growth of data lakes has made storage a critical cost driver. Many provider
Regnology Launches RRH Ascend, Leveraging Straight-Through Reporting to Modernize Financial Regulation19.11.2025 09:00:00 EET | Press release
Regnology, a leading software provider with a focus on regulatory reporting and supervisory technology solutions, today announced the launch of RRH Ascend, the next generation of its Regnology Reporting Hub (RRH) solution for banking and transaction reporting. The unveiling will take place at the 32nd annual RegTech Convention, the largest global conference on financial regulation, which brings together more than 2,000 participants across nine cities in a hybrid format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118412298/en/ RRH Ascend marks a major step towardStraight-Through Reporting (STR)—a new standard designed to eliminate friction in regulatory processes through end-to-end automation, seamless data integration, and intelligent oversight. Modeled on the principles of Straight-Through Processing (STP) in capital markets, STR enables continuous, data-driven exchanges between institutions and regulators, reducing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom